Lung Cancer | Specialty

The Role of Patient Education in Side Effect Management

October 27th 2013

Managing BRAF Inhibitor Associated Skin Toxicity

October 27th 2013

The Nurse's Role in Managing Skin Toxicity

October 27th 2013

Managing mTOR Inhibitor Induced Adverse Events

October 27th 2013

Interdisciplinary Approach to Managing Skin Toxicities

October 27th 2013

Managing Treatment-Related Hand-Foot Skin Reaction

October 27th 2013

Managing BCR-ABL Inhibitor Associated Skin Rash

October 27th 2013

Managing Angiogenesis Inhibitor Related Skin Toxicity

October 27th 2013

Anticipatory Coping in Patients Treated With EGFR Inhibitors

October 27th 2013

Managing EGFR Inhibitor Associated Skin Toxicity

October 27th 2013

Dr. Camidge Discusses Next-Generation Sequencing

October 24th 2013

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, explains excitement over the potential role for next-generation sequencing in cancer care.

Impact of Molecular Testing on First-Line Treatment Decisions in NSCLC

October 18th 2013

Five lung cancer experts discuss recent advances and current issues surrounding the treatment of non-small cell lung cancer

Leveraging Health Reform to Combat a History of Cancer

October 11th 2013

Governor Steve Beshear did not sugarcoat the data on May 9, 2013, when he said Kentucky would take an offer it couldn't refuse. With his state ranked worst in the nation in smoking and cancer deaths, and not far behind in heart disease, Beshear was "tired of being at the bottom."

Expanding TKI Therapy in Advanced Lung Cancer

October 9th 2013

Amid rapid progress in the treatment of advanced lung cancer, several leading organizations have joined in developing new guidelines for the optimal use of molecular testing to help select patients for therapy with tyrosine kinase inhibitors

Dr. Langer on the Treatment of Early Stage Lung Cancer

October 8th 2013

Corey J. Langer, MD, professor of medicine, hematology/oncology division, University of Pennsylvania, Abramson Cancer Center, discusses the treatment of patients with early stage lung cancer.

Precision Cancer Medicine: New Era for Translating Lab Research Is Emerging

October 8th 2013

It is well recognized that advances in cancer management have most often resulted from a close collaboration between clinical and laboratory investigative efforts.

Verastem Targets Cancer Stem Cells

October 8th 2013

Cancer stem cells are an underlying cause of a tumor's ability to recur and metastasize even after initial treatment. Therefore, targeting those cancer stem cells could prove to be a valuable tool in the treatment of several different tumor types.

Dr. Camidge on AP26113 in Advanced Malignancies

October 7th 2013

D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.

Lung Cancer in 2013: Where Are We?

October 4th 2013

Over the past year, there has been a multitude of exciting developments in the treatment of patients with non-small cell lung cancer

Dr. Carbone on Potential Biomarkers in Lung Cancer

October 3rd 2013

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.